- Home
- DYN vs GIII Comparison
DYN vs GIII Comparison
Compare DYN & GIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYN
- GIII
- Stock Information
- Founded
- DYN 1984
- GIII 1956
- Country
- DYN United States
- GIII United States
- Employees
- DYN N/A
- GIII N/A
- Industry
- DYN Medicinal Chemicals and Botanical Products
- GIII Apparel
- Sector
- DYN Health Care
- GIII Consumer Discretionary
- Exchange
- DYN Nasdaq
- GIII Nasdaq
- Market Cap
- DYN 1.3B
- GIII 1.1B
- IPO Year
- DYN 2020
- GIII 1989
- Fundamental
- Price
- DYN $14.70
- GIII $22.51
- Analyst Decision
- DYN Strong Buy
- GIII Buy
- Analyst Count
- DYN 13
- GIII 6
- Target Price
- DYN $45.92
- GIII $32.00
- AVG Volume (30 Days)
- DYN 2.0M
- GIII 526.8K
- Earning Date
- DYN 05-08-2025
- GIII 06-06-2025
- Dividend Yield
- DYN N/A
- GIII N/A
- EPS Growth
- DYN N/A
- GIII 12.17
- EPS
- DYN N/A
- GIII 4.28
- Revenue
- DYN N/A
- GIII $3,154,658,000.00
- Revenue This Year
- DYN N/A
- GIII $0.10
- Revenue Next Year
- DYN N/A
- GIII N/A
- P/E Ratio
- DYN N/A
- GIII $5.26
- Revenue Growth
- DYN N/A
- GIII 1.72
- 52 Week Low
- DYN $6.36
- GIII $20.66
- 52 Week High
- DYN $47.45
- GIII $36.18
- Technical
- Relative Strength Index (RSI)
- DYN 72.20
- GIII 27.38
- Support Level
- DYN $13.14
- GIII $28.02
- Resistance Level
- DYN $12.34
- GIII $29.27
- Average True Range (ATR)
- DYN 0.79
- GIII 1.00
- MACD
- DYN 0.23
- GIII -0.45
- Stochastic Oscillator
- DYN 91.82
- GIII 9.81
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
About GIII G-III Apparel Group LTD.
G-III Apparel Group Ltd is a textile company. It makes a wide range of apparel, footwear, and accessories that it sells under its own brands, licensed brands, and private-label brands. G-III has a substantial portfolio for licensed and proprietary brands, anchored by five global power brands: DKNY, Donna Karan, Calvin Klein, Tommy Hilfiger, and Karl Lagerfeld. The company has two reportable operations: Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, as well as sales of products under its own brands and private label brands. The retail operations segment consists of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives majority of its revenues from Wholesale operations.